Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of “Buy” from Analysts

Caribou Biosciences, Inc. (NASDAQ:CRBU) has been given a consensus rating of “Buy” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.33.

Several equities research analysts have issued reports on CRBU shares. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Wednesday. Citigroup lowered their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Finally, Bank of America decreased their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th.

Caribou Biosciences Stock Up 4.0 %

CRBU stock opened at $1.04 on Friday. Caribou Biosciences has a 52 week low of $0.95 and a 52 week high of $5.62. The company has a market cap of $96.73 million, a price-to-earnings ratio of -0.63 and a beta of 2.34. The business has a fifty day simple moving average of $1.29 and a 200-day simple moving average of $1.74.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. As a group, analysts expect that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Trading of Caribou Biosciences

Several large investors have recently modified their holdings of the business. Centric Wealth Management purchased a new position in Caribou Biosciences in the fourth quarter valued at about $27,000. Erste Asset Management GmbH purchased a new stake in Caribou Biosciences during the 3rd quarter worth approximately $28,000. Russell Investments Group Ltd. raised its position in shares of Caribou Biosciences by 859.0% in the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock valued at $38,000 after purchasing an additional 21,416 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after buying an additional 9,148 shares during the last quarter. Finally, Diametric Capital LP acquired a new stake in shares of Caribou Biosciences during the fourth quarter worth approximately $42,000. 77.51% of the stock is currently owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.